20:27 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

Xpert Xpress Flu/RSV regulatory update

FDA approved the Xpert Xpress Flu/RSV from Danaher’s Cepheid subsidiary to diagnose influenza A and B infections and respiratory syncytial virus (RSV) infection. Xpert Xpress Flu/RSV is a qualitative PCR-based kit that runs on the...
20:27 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

Xpert Xpress Flu regulatory update

FDA approved the Xpert Xpress Flu from Danaher’s Cepheid subsidiary to diagnose influenza A and B infections. Xpert Xpress Flu is a qualitative PCR-based kit that runs on the company's GeneXpert System. Danaher Corp. (NYSE:DHR), Washington,...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Cepheid sales and marketing update

Cepheid launched its Xpert Bladder Cancer Monitor test in Germany to provide information on bladder cancer recurrence. The company said the urine-based test has CE Mark approval. The company did not respond to inquiries. Cepheid...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Company News

Cepheid, Danaher deal

Lab equipment and diagnostics company Danaher is acquiring molecular diagnostic play Cepheid for $53 per share, or about $4 billion including debt and net of cash. The price is a 54% premium to Cepheid’s close...
07:00 , Sep 6, 2016 |  BC Extra  |  Company News

Danaher acquiring Cepheid

Lab equipment and diagnostics company Danaher Corp. (NYSE:DHR) is acquiring molecular diagnostics play Cepheid Inc. (NASDAQ:CPHD) for $53 per share, or about $4 billion including debt and net of cash. The price is a 54%...
07:00 , Jul 25, 2016 |  BioCentury  |  Finance

That was then; this is now

It's impossible to define how much of last week's jump in Biogen Inc. (NASDAQ:BIIB) shares related to CEO George Scangos' pending departure announced Thursday, and how much reflected the strong 2Q16 earnings reported the same...
02:58 , Feb 13, 2016 |  BC Extra  |  Company News

Management tracks

The Association of the British Pharmaceutical Industry named Mike Thompson chief executive, effective March 1. Thompson was SVP of global commercial strategy and platforms at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Cepheid Inc. (NASDAQ:CPHD) promoted COO Warren...
08:00 , Feb 1, 2016 |  BioCentury  |  Finance

Valuing CRISPR/Cas9

Editas Medicine Inc. is looking for a $606.9 million postmoney valuation - the highest of any preclinical biotech IPO since BioCentury started tracking financings in 1994. Even if Editas takes the now-standard 20% IPO haircut,...
08:00 , Dec 7, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg12/4 clsCepheid Inc. (NASDAQ:CPHD)Wells FargoTim EvansDowngradeMarket perform (from outperform)-10%$33.43 Evans also lowered his target to $32-$34 from $35-$37 after the molecular diagnostics company lowered its 2017 non-GAAP gross...
07:00 , Oct 26, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg10/23 clsBiogen Inc. (NASDAQ:BIIB)BairdBrian SkorneyPrice targetNeutral2%$276.99 H.C. WainwrightAndrew FeinPrice targetBuyJefferiesBrian AbrahamsPrice targetBuySkorney lowered his target to $292 from $316. Biogen reported 3Q15 results that beat the Street's estimates;...